It's unclear exactly why Icahn diminished his stake so much, although worries over the
strength of biotech stocks and the market in general might explain the move.
The reason you'll see a
couple of biotech stocks on this list of top performers is because the category slammed the returns of the S&P 500 during the last five years.
While I tend to like ETFs that use equal weighing, it's important for investors to understand that smaller - cap companies tend to be a bit more volatile, and that's especially
true of biotech stocks, which means this ETF might be more prone to even more volatility than a weighted - average ETF would be.
In case you haven't noticed a pattern developing, buying
any of these biotech stocks would be incredibly risky right now.